Michael Feigin


Specializing In:

Cancer cell signaling Cancer genetics Three dimensional cell culture Cell biology

Special Interests:

G-protein coupled receptor signaling Noncoding mutations in cancer Pancreatic cancer Breast cancer Melanoma

About Michael Feigin


Roswell Park Comprehensive Cancer Center

  • Assistant Professor of Oncology
  • Department of Pharmacology & Therapeutics


Education and Training:

  • 2007 - PhD - Molecular and Cellular Pharmacology, State University of New York at Stony Brook, Stony Brook, NY


  • 2017 - Cancer biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY


Research Overview:

Our lab seeks to understand the molecular causes of cancer to develop better therapies and improve patient outcome. Through a combination of computational and experimental methods, we study how genes are regulated in cancer, and how changes in gene regulation and cell signaling networks drive tumor progression.

Feigin Lab


Full Publications list on PubMed

Venkat S and Feigin ME. Alternative polyadenylation characterizes epithelial and fibroblast phenotypic heterogeneity in pancreatic ductal adenocarcinoma. bioRxiv. September 2021

Venkat S, Alahmari AA and Feigin ME. Drivers of gene expression dysregulation in pancreatic cancer. Trends in Cancer. 2021

Cornwell AC and Feigin ME. Unintended effects of GPCR-targeted drugs on the cancer phenotype. Trends in Pharmacological Sciences. 2020

Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH and Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ducal adenocarcinoma. Genome Research. 2020

Feigin ME*, Garvin T*, Bailey P, Waddell N, Chang DK, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics. 2017